Trait: prostate carcinoma

Experimental Factor Ontology (EFO) Information
Identifier EFO_0001663
Description A carcinoma that arises from epithelial cells of the prostate gland.
Trait category
Cancer
Synonyms 5 synonyms
  • carcinoma of prostate
  • carcinoma of prostate gland
  • carcinoma of the prostate
  • prostate carcinoma
  • prostate gland carcinoma
Mapped terms 7 mapped terms
  • DOID:10286
  • EFO:0001663
  • KEGG:05215
  • MONDO:0005159
  • NCIT:C4863
  • OMIM:176807
  • UMLS:C0600139

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution Scoring File (FTP Link)
PGS000030
(PrCa)
PGP000019 |
Schumacher FR et al. Nat Genet (2018)
Prostate cancer prostate carcinoma 147
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000030/ScoringFiles/PGS000030.txt.gz
PGS000044
(PrCa66)
PGP000031 |
Pashayan N et al. Br J Cancer (2015)
Prostate cancer prostate carcinoma 66
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000044/ScoringFiles/PGS000044.txt.gz
PGS000049
(PRS103_PrCa)
PGP000034 |
Lecarpentier J et al. J Clin Oncol (2017)
Prostate Cancer prostate carcinoma 103
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000049/ScoringFiles/PGS000049.txt.gz
PGS000067
(PCa_PHS)
PGP000047 |
Seibert TM et al. BMJ (2018)
Prostate cancer prostate carcinoma 54
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000067/ScoringFiles/PGS000067.txt.gz
PGS000084
(CC_Prostate)
PGP000050 |
Graff RE et al. Nat Commun (2021)
Prostate cancer prostate carcinoma 161
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000084/ScoringFiles/PGS000084.txt.gz
PGS000160
(cGRS_Prostate)
PGP000075 |
Shi Z et al. Cancer Med (2019)
Prostate cancer prostate carcinoma 79
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000160/ScoringFiles/PGS000160.txt.gz
PGS000333
(PRS_PC)
PGP000100 |
Mars N et al. Nat Med (2020)
Prostate cancer prostate carcinoma 6,606,785
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000333/ScoringFiles/PGS000333.txt.gz
PGS000348
(PRS_PrCa)
PGP000113 |
Black MH et al. Prostate (2020)
Prostate cancer prostate carcinoma 72
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000348/ScoringFiles/PGS000348.txt.gz - Check Terms/Licenses
PGS000565
(PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 21
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000565/ScoringFiles/PGS000565.txt.gz
PGS000566
(PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,111,494
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000566/ScoringFiles/PGS000566.txt.gz
PGS000567
(PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 78
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000567/ScoringFiles/PGS000567.txt.gz
PGS000568
(PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,401
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000568/ScoringFiles/PGS000568.txt.gz
PGS000569
(PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 49
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000569/ScoringFiles/PGS000569.txt.gz
PGS000570
(PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,111,493
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000570/ScoringFiles/PGS000570.txt.gz
PGS000571
(PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 100
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000571/ScoringFiles/PGS000571.txt.gz
PGS000572
(PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,809
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000572/ScoringFiles/PGS000572.txt.gz
PGS000573
(PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 31
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000573/ScoringFiles/PGS000573.txt.gz
PGS000574
(PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,111,493
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000574/ScoringFiles/PGS000574.txt.gz
PGS000575
(PRSWEB_PHECODE185_C61_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 47
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000575/ScoringFiles/PGS000575.txt.gz
PGS000576
(PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 905
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000576/ScoringFiles/PGS000576.txt.gz
PGS000577
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 117
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000577/ScoringFiles/PGS000577.txt.gz
PGS000578
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 117
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000578/ScoringFiles/PGS000578.txt.gz
PGS000579
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 122
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000579/ScoringFiles/PGS000579.txt.gz
PGS000580
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 118
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000580/ScoringFiles/PGS000580.txt.gz
PGS000581
(PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 377
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000581/ScoringFiles/PGS000581.txt.gz
PGS000582
(PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 377
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000582/ScoringFiles/PGS000582.txt.gz
PGS000583
(PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,119,311
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000583/ScoringFiles/PGS000583.txt.gz
PGS000584
(PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,120,596
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000584/ScoringFiles/PGS000584.txt.gz
PGS000585
(PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,301
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000585/ScoringFiles/PGS000585.txt.gz
PGS000586
(PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,023
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000586/ScoringFiles/PGS000586.txt.gz
PGS000587
(PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 26,418
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000587/ScoringFiles/PGS000587.txt.gz
PGS000588
(PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 178,259
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000588/ScoringFiles/PGS000588.txt.gz
PGS000589
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 42
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000589/ScoringFiles/PGS000589.txt.gz
PGS000590
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,119,236
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000590/ScoringFiles/PGS000590.txt.gz
PGS000591
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 80
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000591/ScoringFiles/PGS000591.txt.gz
PGS000592
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Cancer of prostate prostate carcinoma 1,334
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000592/ScoringFiles/PGS000592.txt.gz
PGS000662
(GRS.PCa.269)
PGP000122 |
Conti DV et al. Nat Genet (2021)
Prostate Cancer prostate carcinoma 269
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000662/ScoringFiles/PGS000662.txt.gz
PGS000714
(PRS55_PC)
PGP000130 |
Sipeky C et al. Sci Rep (2020)
Prostate cancer prostate carcinoma 55
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000714/ScoringFiles/PGS000714.txt.gz
PGS000719
(PRS_Prostate)
PGP000135 |
Jia G et al. JNCI Cancer Spectr (2020)
Prostate cancer prostate carcinoma 134
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000719/ScoringFiles/PGS000719.txt.gz
PGS000733
(PHS46+African)
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
Prostate cancer prostate carcinoma 49
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000733/ScoringFiles/PGS000733.txt.gz
PGS000741
(PCa_PHS2)
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Prostate cancer prostate carcinoma 46
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000741/ScoringFiles/PGS000741.txt.gz
PGS000742
(PHS166)
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Prostate cancer prostate carcinoma 166
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000742/ScoringFiles/PGS000742.txt.gz
PGS000751
(PRS_PrCa_EuropeanWeighted)
PGP000156 |
Du Z et al. Int J Cancer (2019)
Prostate cancer prostate carcinoma 178
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000751/ScoringFiles/PGS000751.txt.gz
PGS000795
(CC_Prostate_IV)
PGP000186 |
Kachuri L et al. Nat Commun (2020)
Prostate cancer prostate carcinoma 161
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000795/ScoringFiles/PGS000795.txt.gz
PGS000878
(PRS4_PC)
PGP000224 |
Oh JJ et al. Front Oncol (2020)
Prostate cancer prostate carcinoma 4
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000878/ScoringFiles/PGS000878.txt.gz
PGS000881
(GRS72_PCa)
PGP000227 |
Xu J et al. Prostate (2021)
Prostate cancer prostate carcinoma 72
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000881/ScoringFiles/PGS000881.txt.gz
PGS001291
(GBE_cancer1044)
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Prostate cancer prostate carcinoma 948
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001291/ScoringFiles/PGS001291.txt.gz
PGS001805
(portability-PLR_185)
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Cancer of prostate prostate carcinoma 2,579
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001805/ScoringFiles/PGS001805.txt.gz
PGS002016
(portability-ldpred2_185)
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Cancer of prostate prostate carcinoma 450,963
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002016/ScoringFiles/PGS002016.txt.gz
PGS002240
(prscs_prostatecancer)
PGP000271 |
Mars N et al. Cell Genom (2022)
Prostate cancer prostate carcinoma 1,092,093
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002240/ScoringFiles/PGS002240.txt.gz
PGS002241
(ldpred_prostatecancer)
PGP000271 |
Mars N et al. Cell Genom (2022)
Prostate cancer prostate carcinoma 6,497,734
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002241/ScoringFiles/PGS002241.txt.gz
PGS002268
(PRS_csPCa)
PGP000298 |
Song SH et al. Investig Clin Urol (2022)
Prostate cancer prostate carcinoma 29
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002268/ScoringFiles/PGS002268.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM000061 PGS000030
(PrCa)
PSS000041|
European Ancestry|
74,849 individuals
PGP000019 |
Schumacher FR et al. Nat Genet (2018)
Reported Trait: Prostate cancer OR: 1.86 [1.83, 1.89] Top 7 Genetic PCs, country Samples were also part of the variant association
PPM001971 PGS000030
(PrCa)
PSS000983|
European Ancestry|
81,094 individuals
PGP000173 |
Darst BF et al. Eur Urol (2021)
|Ext.
Reported Trait: Prostate cancer in carriers of rare pathogenic, likely pathogenic and/or deleterious germline variants OR: 2.58 [2.45, 2.71] Age, PCs (1-10) Only 145 SNPs from PGS000030 were utilised. 2 SNPs were not included as they were not present in the UK Biobank (UKB) data and had an imputation info score of > 0.50 (median info score = 0.997).
PPM005133 PGS000030
(PrCa)
PSS003583|
European Ancestry|
450 individuals
PGP000245 |
Barnes DR et al. J Natl Cancer Inst (2021)
|Ext.
Reported Trait: Prostate cancer in BRCA1 carriers OR: 1.73 [1.28, 2.33] AUROC: 0.62 [0.54, 0.69] PCs(1-3)
PPM005134 PGS000030
(PrCa)
PSS003583|
European Ancestry|
450 individuals
PGP000245 |
Barnes DR et al. J Natl Cancer Inst (2021)
|Ext.
Reported Trait: Prostate cancer in BRCA1 carriers OR: 1.74 [1.29, 2.35] PCs(1-3), family history of prostate cancer in first and second degree relatives
PPM005135 PGS000030
(PrCa)
PSS003584|
European Ancestry|
1,074 individuals
PGP000245 |
Barnes DR et al. J Natl Cancer Inst (2021)
|Ext.
Reported Trait: Prostate cancer in BRCA2 carriers OR: 1.6 [1.34, 1.91] AUROC: 0.62 [0.57, 0.67] PCs(1-3)
PPM005136 PGS000030
(PrCa)
PSS003584|
European Ancestry|
1,074 individuals
PGP000245 |
Barnes DR et al. J Natl Cancer Inst (2021)
|Ext.
Reported Trait: Prostate cancer in BRCA2 carriers OR: 1.59 [1.32, 1.9] PCs(1-3), family history of prostate cancer in first and second degree relatives
PPM012886 PGS000030
(PrCa)
PSS009594|
Ancestry Not Reported|
4,580 individuals
PGP000292 |
Saad M et al. Lancet Oncol (2022)
|Ext.
Reported Trait: Prostate cancer OR: 1.835 [1.664, 2.023] AUROC: 0.672 [0.645, 0.698]
PPM013015 PGS000030
(PrCa)
PSS009648|
European Ancestry|
991 individuals
PGP000322 |
Klein RJ et al. NPJ Precis Oncol (2022)
|Ext.
Reported Trait: Prostate cancer metastasis or death HR: 1.25 [1.1, 1.41]
PPM013016 PGS000030
(PrCa)
PSS009649|
European Ancestry|
1,000 individuals
PGP000322 |
Klein RJ et al. NPJ Precis Oncol (2022)
|Ext.
Reported Trait: Prostate cancer metastasis or death HR: 1.65
PPM013017 PGS000030
(PrCa)
PSS009648|
European Ancestry|
991 individuals
PGP000322 |
Klein RJ et al. NPJ Precis Oncol (2022)
|Ext.
Reported Trait: Incident prostate cancer HR: 1.25 [1.11, 1.41]
PPM013018 PGS000030
(PrCa)
PSS009649|
European Ancestry|
1,000 individuals
PGP000322 |
Klein RJ et al. NPJ Precis Oncol (2022)
|Ext.
Reported Trait: Incident prostate cancer HR: 1.69
PPM013019 PGS000030
(PrCa)
PSS009650|
European Ancestry|
1,991 individuals
PGP000322 |
Klein RJ et al. NPJ Precis Oncol (2022)
|Ext.
Reported Trait: Prostate cancer metastasis or death AUROC: 0.63
PPM000105 PGS000044
(PrCa66)
PSS000069|
European Ancestry|
4,967 individuals
PGP000032 |
Pashayan N et al. Genet Med (2015)
|Ext.
Reported Trait: aggressive prostate cancer (Gleason score ⩾7) OR (above vs. below 50th percentile of PRS): 1.56 [1.15, 2.1]
PPM000104 PGS000044
(PrCa66)
PSS000068|
European Ancestry|
17,012 individuals
PGP000031 |
Pashayan N et al. Br J Cancer (2015)
Reported Trait: Elevated serum prostate-specific antigen (PSA) levels OR (per 1-point increase in PRS): 1.23 [1.1, 1.37] cancer stage, Gleason score
PPM000123 PGS000049
(PRS103_PrCa)
PSS000075|
European Ancestry|
1,525 individuals
PGP000034 |
Lecarpentier J et al. J Clin Oncol (2017)
Reported Trait: Prostate cancer in male carriers of BRCA1/2 mutations OR: 1.56 [1.35, 1.81] AUROC: 0.62 [0.58, 0.66] 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2
PPM000124 PGS000049
(PRS103_PrCa)
PSS000077|
European Ancestry|
1,366 individuals
PGP000034 |
Lecarpentier J et al. J Clin Oncol (2017)
Reported Trait: Low prostate cancer aggressiveness (Gleason score < 7) OR: 1.44 [1.1, 1.87] 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2
PPM000125 PGS000049
(PRS103_PrCa)
PSS000076|
European Ancestry|
3,325 individuals
PGP000034 |
Lecarpentier J et al. J Clin Oncol (2017)
Reported Trait: High prostate cancer aggressiveness (Gleason score ≥ 7) OR: 1.67 [1.37, 2.04] 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2
PPM000182 PGS000067
(PCa_PHS)
PSS000105|
European Ancestry|
5,456 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: aggressive prostate cancer HR (Hazard ratio; top 2% vs. average risk): 2.9 [2.4, 3.4]
PPM000184 PGS000067
(PCa_PHS)
PSS000106|
European Ancestry|
6,411 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: any prostate cancer HR (Hazard ratio; top 2% vs. average risk): 2.5 [2.2, 2.8]
PPM001675 PGS000067
(PCa_PHS)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
|Ext.
Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR top 2% vs. middle 40%): 2.1 [1.99, 2.21] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001677 PGS000067
(PCa_PHS)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
|Ext.
Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR bottom 20% vs. middle 40%): 0.65 [0.63, 0.67] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000393 PGS000067
(PCa_PHS)
PSS000221|
African Ancestry|
4,437 individuals
PGP000058 |
Huynh-Le M et al. medRxiv (2019)
|Ext.|Pre
Reported Trait: Age of aggressive prostate cancer onset Hazard Ratio (HR; top 20% vs. rest): 2.4 [2.3, 2.6] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000392 PGS000067
(PCa_PHS)
PSS000222|
Additional Asian Ancestries|
1,901 individuals
PGP000058 |
Huynh-Le M et al. medRxiv (2019)
|Ext.|Pre
Reported Trait: Age of aggressive prostate cancer onset Hazard Ratio (HR; top 20% vs. rest): 5.2 [4.8, 5.6] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000391 PGS000067
(PCa_PHS)
PSS000223|
European Ancestry|
50,656 individuals
PGP000058 |
Huynh-Le M et al. medRxiv (2019)
|Ext.|Pre
Reported Trait: Age of aggressive prostate cancer onset Hazard Ratio (HR; top 20% vs. rest): 5.6 [5.2, 6.0] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000390 PGS000067
(PCa_PHS)
PSS000220|
Multi-ancestry (including European)|
56,994 individuals
PGP000058 |
Huynh-Le M et al. medRxiv (2019)
|Ext.|Pre
Reported Trait: Age of aggressive prostate cancer onset Hazard Ratio (HR; top 20% vs. rest): 5.9 [5.5, 6.3] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001679 PGS000067
(PCa_PHS)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
|Ext.
Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (HR top 20% vs. bottom 20%): 2.21 [2.04, 2.38] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000394 PGS000067
(PCa_PHS)
PSS000224|
Multi-ancestry (including European)|
34,558 individuals
PGP000058 |
Huynh-Le M et al. medRxiv (2019)
|Ext.|Pre
Reported Trait: Age of prostate cancer death Hazard Ratio (HR; top 20% vs. rest): 5.7 [4.6, 7.0] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001683 PGS000067
(PCa_PHS)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
|Ext.
Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (bottom 20% vs. middle 40%): 0.7 [0.68, 0.73] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001681 PGS000067
(PCa_PHS)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
|Ext.
Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (top 2% vs. middle 40%): 1.91 [1.79, 2.04] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000186 PGS000067
(PCa_PHS)
PSS000107|
European Ancestry|
5,048 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: very aggressive prostate cancer HR (Hazard ratio; top 2% vs. average risk): 3.0 [2.2, 4.0]
PPM001673 PGS000067
(PCa_PHS)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
|Ext.
Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR top 20% vs. bottom 20%): 2.47 [2.32, 2.62] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001812 PGS000067
(PCa_PHS)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Prostate cancer (age of onset) Hazard Ratio (HR, top 20% vs. bottom 20%): 5.15 [3.29, 6.18] Only 46 out of the 54 variants were used from Seibert et al's polygenic risk score (PGS000067)
PPM001813 PGS000067
(PCa_PHS)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Prostate cancer (age of onset) Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.44 [0.4, 0.49] Only 46 out of the 54 variants were used from Seibert et al's polygenic risk score (PGS000067)
PPM001817 PGS000067
(PCa_PHS)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Clinically significant prostate cancer (age at onset) Hazard Ratio (HR, top 5% vs. middle 40%): 3.72 [2.89, 4.43] Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067)
PPM001818 PGS000067
(PCa_PHS)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Clinically significant prostate cancer (age at onset) Hazard Ratio (HR, top 20% vs. bottom 20%): 6.12 [4.18, 7.67] Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067)
PPM001819 PGS000067
(PCa_PHS)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Clinically significant prostate cancer (age at onset) Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.41 [0.35, 0.47] Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067)
PPM001823 PGS000067
(PCa_PHS)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Non-clinically significant prostate cancer (age at onset) Hazard Ratio (HR, top 5% vs. middle 40%): 3.2 [2.59, 3.78] Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067)
PPM001824 PGS000067
(PCa_PHS)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Non-clinically significant prostate cancer (age at onset) Hazard Ratio (HR, top 20% vs. bottom 20%): 4.96 [3.61, 6.14] Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067)
PPM001825 PGS000067
(PCa_PHS)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Non-clinically significant prostate cancer (age at onset) Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.45 [0.39, 0.5] Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067)
PPM001811 PGS000067
(PCa_PHS)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Prostate cancer (age of onset) Hazard Ratio (HR, top 5% vs. middle 40%): 3.29 [2.73, 3.77] Only 46 out of the 54 variants were used from Seibert et al's polygenic risk score (PGS000067)
PPM000187 PGS000067
(PCa_PHS)
PSS000107|
European Ancestry|
5,048 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: very aggressive prostate cancer (age at onset) z-test (p-value) <: 1.00e-16
PPM000183 PGS000067
(PCa_PHS)
PSS000105|
European Ancestry|
5,456 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: aggressive prostate cancer (age at onset) z-test (p-value) <: 1.00e-16
PPM000185 PGS000067
(PCa_PHS)
PSS000106|
European Ancestry|
6,411 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: any prostate cancer (age at onset) z-test (p-value) <: 1.00e-16
PPM000204 PGS000084
(CC_Prostate)
PSS000123|
European Ancestry|
201,516 individuals
PGP000050 |
Graff RE et al. Nat Commun (2021)
Reported Trait: Prostate cancer OR: 1.44 [1.41, 1.47] Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. Results from meta-analysis of GERA and UKB. Sample overlap: the GERA dataset contributed to the effect estimates for 4 of the 161 variants in the prostate cancer PRS.
PPM002050 PGS000084
(CC_Prostate)
PSS001023|
European Ancestry|
184,225 individuals
PGP000186 |
Kachuri L et al. Nat Commun (2020)
|Ext.
Reported Trait: Incident prostate cancer HR: 1.39 [1.35, 1.43] AUROC: 0.74
C-index: 0.738 (0.004)
Age at assessment, family history of prostate cancer, genotyping array, PCs(1-15), family history of prostate cancer C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years.
PPM000491 PGS000160
(cGRS_Prostate)
PSS000280|
European Ancestry|
6,828 individuals
PGP000075 |
Shi Z et al. Cancer Med (2019)
Reported Trait: Prostate cancer Odds Ratio (OR; high vs. average risk groups): 1.73 [1.38, 2.17]
PPM000480 PGS000160
(cGRS_Prostate)
PSS000280|
European Ancestry|
6,828 individuals
PGP000075 |
Shi Z et al. Cancer Med (2019)
Reported Trait: Prostate cancer Mean realative risk: 1.3 [1.21, 1.38]
Wilcoxon test (case vs. control) p-value: 2.07e-18
PPM000900 PGS000333
(PRS_PC)
PSS000447|
European Ancestry|
48,851 individuals
PGP000100 |
Mars N et al. Nat Med (2020)
Reported Trait: Incident prostate cancer C-index: 0.866 age, family history, history of benign prostate hyperplasia, genotyping array/batch, 10 ancestry PCs 10-year risk
PPM000895 PGS000333
(PRS_PC)
PSS000447|
European Ancestry|
48,851 individuals
PGP000100 |
Mars N et al. Nat Med (2020)
Reported Trait: Incident prostate cancer C-index: 0.857 age, genotyping array/batch, 10 ancestry PCs 10-year risk
PPM000890 PGS000333
(PRS_PC)
PSS000446|
European Ancestry|
59,126 individuals
PGP000100 |
Mars N et al. Nat Med (2020)
Reported Trait: Prostate cancer (incident and prevalent cases) HR: 1.83 [1.78, 1.9] genotyping array/batch, 10 ancestry PCs
PPM000987 PGS000348
(PRS_PrCa)
PSS000502|
European Ancestry|
1,039 individuals
PGP000113 |
Black MH et al. Prostate (2020)
Reported Trait: Prostate cancer in men with a family history of prostate cancer OR: 1.9 [1.53, 2.4] Age
PPM000986 PGS000348
(PRS_PrCa)
PSS000501|
European Ancestry|
3,891 individuals
PGP000113 |
Black MH et al. Prostate (2020)
Reported Trait: Prostate cancer AUROC: 0.64 Age
PPM000985 PGS000348
(PRS_PrCa)
PSS000501|
European Ancestry|
3,891 individuals
PGP000113 |
Black MH et al. Prostate (2020)
Reported Trait: Prostate cancer OR: 1.72 [1.59, 1.88] AUROC: 0.64 [0.62, 0.66]
PPM000988 PGS000348
(PRS_PrCa)
PSS000503|
European Ancestry|
2,305 individuals
PGP000113 |
Black MH et al. Prostate (2020)
Reported Trait: Prostate cancer in men with no family history of prostate cancer OR: 1.65 [1.49, 1.84] Age
PPM001250 PGS000565
(PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.434 [1.336, 1.54]
β: 0.361 (0.0363)
AUROC: 0.596 [0.579, 0.615] Nagelkerke's Pseudo-R²: 0.0271
Brier score: 0.151
Odds Ratio (OR, top 1% vs. Rest): 2.39 [1.41, 4.03]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608
PPM001251 PGS000566
(PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.393 [1.3, 1.493]
β: 0.332 (0.0352)
AUROC: 0.591 [0.573, 0.609] Nagelkerke's Pseudo-R²: 0.0245
Brier score: 0.152
Odds Ratio (OR, top 1% vs. Rest): 2.85 [1.76, 4.62]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608
PPM001252 PGS000567
(PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.505 [1.404, 1.613]
β: 0.409 (0.0354)
AUROC: 0.608 [0.59, 0.628] Nagelkerke's Pseudo-R²: 0.0379
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 3.17 [1.98, 5.06]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608
PPM001253 PGS000568
(PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.426 [1.332, 1.527]
β: 0.355 (0.035)
AUROC: 0.595 [0.577, 0.614] Nagelkerke's Pseudo-R²: 0.0281
Brier score: 0.151
Odds Ratio (OR, top 1% vs. Rest): 1.53 [0.88, 2.66]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608
PPM001254 PGS000569
(PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.643 [1.531, 1.763]
β: 0.496 (0.036)
AUROC: 0.63 [0.613, 0.648] Nagelkerke's Pseudo-R²: 0.0543
Brier score: 0.148
Odds Ratio (OR, top 1% vs. Rest): 2.86 [1.79, 4.57]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608
PPM001255 PGS000570
(PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.572 [1.465, 1.687]
β: 0.452 (0.0359)
AUROC: 0.622 [0.604, 0.639] Nagelkerke's Pseudo-R²: 0.0453
Brier score: 0.149
Odds Ratio (OR, top 1% vs. Rest): 2.66 [1.63, 4.34]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608
PPM001256 PGS000571
(PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.67 [1.555, 1.793]
β: 0.513 (0.0363)
AUROC: 0.634 [0.617, 0.653] Nagelkerke's Pseudo-R²: 0.0583
Brier score: 0.148
Odds Ratio (OR, top 1% vs. Rest): 2.96 [1.85, 4.74]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608
PPM001257 PGS000572
(PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.537 [1.433, 1.649]
β: 0.43 (0.0358)
AUROC: 0.616 [0.597, 0.636] Nagelkerke's Pseudo-R²: 0.0418
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.59, 6.28]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608
PPM001258 PGS000573
(PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.603 [1.495, 1.718]
β: 0.472 (0.0355)
AUROC: 0.622 [0.603, 0.641] Nagelkerke's Pseudo-R²: 0.0497
Brier score: 0.149
Odds Ratio (OR, top 1% vs. Rest): 2.93 [1.83, 4.7]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608
PPM001259 PGS000574
(PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.506 [1.406, 1.614]
β: 0.41 (0.0352)
AUROC: 0.612 [0.593, 0.63] Nagelkerke's Pseudo-R²: 0.039
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.24, 3.52]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608
PPM001260 PGS000575
(PRSWEB_PHECODE185_C61_PT_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.577 [1.47, 1.692]
β: 0.456 (0.0359)
AUROC: 0.619 [0.601, 0.637] Nagelkerke's Pseudo-R²: 0.0456
Brier score: 0.149
Odds Ratio (OR, top 1% vs. Rest): 3.1 [1.96, 4.92]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PT_MGI_20200608
PPM001261 PGS000576
(PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.489 [1.39, 1.596]
β: 0.398 (0.0353)
AUROC: 0.607 [0.589, 0.627] Nagelkerke's Pseudo-R²: 0.0358
Brier score: 0.151
Odds Ratio (OR, top 1% vs. Rest): 2.46 [1.5, 4.01]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608
PPM001262 PGS000577
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.756 [1.634, 1.886]
β: 0.563 (0.0366)
AUROC: 0.646 [0.627, 0.665] Nagelkerke's Pseudo-R²: 0.0678
Brier score: 0.147
Odds Ratio (OR, top 1% vs. Rest): 3.57 [2.29, 5.57]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608
PPM001263 PGS000578
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608)
PSS000573|
European Ancestry|
32,664 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.746 [1.681, 1.813]
β: 0.557 (0.0192)
AUROC: 0.653 [0.642, 0.662] Nagelkerke's Pseudo-R²: 0.0565
Brier score: 0.0813
Odds Ratio (OR, top 1% vs. Rest): 4.31 [3.48, 5.33]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608
PPM001264 PGS000579
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.747 [1.626, 1.876]
β: 0.558 (0.0364)
AUROC: 0.646 [0.627, 0.664] Nagelkerke's Pseudo-R²: 0.0675
Brier score: 0.147
Odds Ratio (OR, top 1% vs. Rest): 3.53 [2.26, 5.51]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608
PPM001265 PGS000580
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608)
PSS000573|
European Ancestry|
32,664 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.748 [1.684, 1.815]
β: 0.559 (0.0192)
AUROC: 0.653 [0.643, 0.663] Nagelkerke's Pseudo-R²: 0.0568
Brier score: 0.0813
Odds Ratio (OR, top 1% vs. Rest): 4.34 [3.51, 5.37]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608
PPM001266 PGS000581
(PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.79 [1.665, 1.925]
β: 0.582 (0.0371)
AUROC: 0.651 [0.634, 0.669] Nagelkerke's Pseudo-R²: 0.071
Brier score: 0.146
Odds Ratio (OR, top 1% vs. Rest): 4.44 [2.87, 6.87]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608
PPM001267 PGS000582
(PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608)
PSS000573|
European Ancestry|
32,664 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.957 [1.882, 2.035]
β: 0.671 (0.0201)
AUROC: 0.681 [0.671, 0.692] Nagelkerke's Pseudo-R²: 0.0776
Brier score: 0.0803
Odds Ratio (OR, top 1% vs. Rest): 4.85 [3.95, 5.95]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608
PPM001268 PGS000583
(PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.929 [1.79, 2.078]
β: 0.657 (0.038)
AUROC: 0.668 [0.651, 0.687] Nagelkerke's Pseudo-R²: 0.0874
Brier score: 0.145
Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.28, 5.72]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608
PPM001269 PGS000584
(PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608)
PSS000573|
European Ancestry|
32,664 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 2.173 [2.087, 2.263]
β: 0.776 (0.0206)
AUROC: 0.705 [0.695, 0.715] Nagelkerke's Pseudo-R²: 0.1
Brier score: 0.0791
Odds Ratio (OR, top 1% vs. Rest): 5.58 [4.58, 6.78]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608
PPM001270 PGS000585
(PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.907 [1.771, 2.053]
β: 0.645 (0.0378)
AUROC: 0.67 [0.652, 0.688] Nagelkerke's Pseudo-R²: 0.0837
Brier score: 0.145
Odds Ratio (OR, top 1% vs. Rest): 3.3 [2.06, 5.29]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608
PPM001271 PGS000586
(PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608)
PSS000573|
European Ancestry|
32,664 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 2.018 [1.94, 2.1]
β: 0.702 (0.0203)
AUROC: 0.687 [0.678, 0.698] Nagelkerke's Pseudo-R²: 0.0837
Brier score: 0.0799
Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.84, 7.13]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608
PPM001272 PGS000587
(PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.906 [1.771, 2.051]
β: 0.645 (0.0375)
AUROC: 0.665 [0.647, 0.684] Nagelkerke's Pseudo-R²: 0.0861
Brier score: 0.145
Odds Ratio (OR, top 1% vs. Rest): 4.92 [3.21, 7.55]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608
PPM001273 PGS000588
(PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608)
PSS000573|
European Ancestry|
32,664 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 2.127 [2.043, 2.215]
β: 0.755 (0.0206)
AUROC: 0.699 [0.69, 0.71] Nagelkerke's Pseudo-R²: 0.0943
Brier score: 0.0794
Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.85, 7.14]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608
PPM001274 PGS000589
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.63 [1.52, 1.748]
β: 0.489 (0.0356)
AUROC: 0.63 [0.612, 0.648] Nagelkerke's Pseudo-R²: 0.0532
Brier score: 0.148
Odds Ratio (OR, top 1% vs. Rest): 3.14 [1.99, 4.96]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608
PPM001275 PGS000590
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.516 [1.415, 1.624]
β: 0.416 (0.0353)
AUROC: 0.614 [0.595, 0.633] Nagelkerke's Pseudo-R²: 0.0395
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.42, 3.78]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608
PPM001276 PGS000591
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.608 [1.498, 1.725]
β: 0.475 (0.0359)
AUROC: 0.627 [0.608, 0.645] Nagelkerke's Pseudo-R²: 0.051
Brier score: 0.149
Odds Ratio (OR, top 1% vs. Rest): 3.18 [2.01, 5.02]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608
PPM001277 PGS000592
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608)
PSS000552|
European Ancestry|
5,607 individuals
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Reported Trait: Cancer of prostate OR: 1.537 [1.433, 1.648]
β: 0.43 (0.0357)
AUROC: 0.616 [0.598, 0.635] Nagelkerke's Pseudo-R²: 0.0408
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.55, 4.2]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608
PPM001365 PGS000662
(GRS.PCa.269)
PSS000596|
European Ancestry|
199,969 individuals
PGP000122 |
Conti DV et al. Nat Genet (2021)
Reported Trait: Prostate Cancer AUROC: 0.833 Odds ratio (OR, top 10% versus 40-60% GRS): 4.17
Overall Net Reclassification Index (NRI [%]): 59.4
Age, 10 PCs
PPM001366 PGS000662
(GRS.PCa.269)
PSS000595|
African Ancestry|
2,633 individuals
PGP000122 |
Conti DV et al. Nat Genet (2021)
Reported Trait: Prostate Cancer AUROC: 0.679 Odds ratio (OR, top 10% versus 40-60% GRS): 3.53 Age, 10 PCs, study
PPM001951 PGS000662
(GRS.PCa.269)
PSS000976|
European Ancestry|
12,472 individuals
PGP000168 |
Plym A et al. J Natl Cancer Inst (2021)
|Ext.
Reported Trait: Prevalent prostate cancer OR: 2.04 Odds ratio (OR, top 10% vs. middle 20%): 3.89 [3.24, 4.68] Age at blood collection, genotyping platform, PCs(1-10) Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome.
PPM001952 PGS000662
(GRS.PCa.269)
PSS000976|
European Ancestry|
12,472 individuals
PGP000168 |
Plym A et al. J Natl Cancer Inst (2021)
|Ext.
Reported Trait: Prevalent prostate cancer Odds ratio (OR, bottom 10% vs. middle 20%): 0.34 [0.25, 0.46] Age at blood collection, genotyping platform, PCs(1-10) Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome.
PPM001953 PGS000662
(GRS.PCa.269)
PSS000976|
European Ancestry|
12,472 individuals
PGP000168 |
Plym A et al. J Natl Cancer Inst (2021)
|Ext.
Reported Trait: Elevated prostate specific antigen OR: 1.54 Age at blood collection, genotyping platform, PCs(1-10) Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome.
PPM001954 PGS000662
(GRS.PCa.269)
PSS000975|
African Ancestry|
524 individuals
PGP000168 |
Plym A et al. J Natl Cancer Inst (2021)
|Ext.
Reported Trait: Prevalent prostate cancer Odds ratio (OR, top 10% vs. middle 20%): 3.81 [1.48, 10.19] Age at blood collection, genotyping platform, PCs(1-2) Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome.
PPM001955 PGS000662
(GRS.PCa.269)
PSS000975|
African Ancestry|
524 individuals
PGP000168 |
Plym A et al. J Natl Cancer Inst (2021)
|Ext.
Reported Trait: Prevalent prostate cancer Odds ratio (OR, bottom 10% vs. middle 20%): 0.15 [0.01, 0.92] Age at blood collection, genotyping platform, PCs(1-2) Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome.
PPM001970 PGS000662
(GRS.PCa.269)
PSS000983|
European Ancestry|
81,094 individuals
PGP000173 |
Darst BF et al. Eur Urol (2021)
|Ext.
Reported Trait: Prostate cancer in carriers of rare pathogenic, likely pathogenic and/or deleterious germline variants OR: 2.62 [2.51, 2.74] Age, PCs (1-10) Only 267 SNPs from PGS000662 were utilised. 2 SNPs were not included as they were not present in the UK Biobank (UKB) data and had an imputation info score of > 0.50 (median info score = 0.99).
PPM012964 PGS000662
(GRS.PCa.269)
PSS009633|
Multi-ancestry (including European)|
110,706 individuals
PGP000308 |
Schaid DJ et al. Am J Hum Genet (2022)
|Ext.
Reported Trait: Prostate cancer Relative Risk (RR): 2.14 [2.09, 2.19] Ancestry, study
PPM012965 PGS000662
(GRS.PCa.269)
PSS009632|
European Ancestry|
91,623 individuals
PGP000308 |
Schaid DJ et al. Am J Hum Genet (2022)
|Ext.
Reported Trait: Prostate cancer Relative Risk (RR: 30 - 55 years old): 2.56 [2.47, 2.65]
Relative Risk (RR: 55 - 60 years old): 2.39
Relative Risk (RR: 60 - 65 years old): 2.24
Relative Risk (RR: 65 - 70 years old): 2.04
Relative risk per adjusted standard error (OPERA) per year of age: 0.00014
Relative Risk (RR: 70 - 88 years old): 1.86 [1.76, 1.98]
PPM001624 PGS000714
(PRS55_PC)
PSS000840|
European Ancestry|
5,138 individuals
PGP000130 |
Sipeky C et al. Sci Rep (2020)
Reported Trait: Prostate cancer OR: 2.13 [1.9, 2.39] AUROC: 0.618 [0.6, 0.63]
PPM001625 PGS000714
(PRS55_PC)
PSS000841|
European Ancestry|
4,683 individuals
PGP000130 |
Sipeky C et al. Sci Rep (2020)
Reported Trait: Prostate cancer (clinical cases) OR: 2.18 [1.93, 2.45] AUROC: 0.622 [0.61, 0.64]
PPM001626 PGS000714
(PRS55_PC)
PSS000843|
European Ancestry|
2,855 individuals
PGP000130 |
Sipeky C et al. Sci Rep (2020)
Reported Trait: Prostate cancer (screening trial detected) OR: 1.92 [1.56, 2.37] AUROC: 0.597 [0.57, 0.63]
PPM001627 PGS000714
(PRS55_PC)
PSS000842|
European Ancestry|
2,591 individuals
PGP000130 |
Sipeky C et al. Sci Rep (2020)
Reported Trait: Metastatic prostate cancer OR: 1.47 AUROC: 0.549
PPM001644 PGS000719
(PRS_Prostate)
PSS000860|
European Ancestry|
400,812 individuals
PGP000135 |
Jia G et al. JNCI Cancer Spectr (2020)
Reported Trait: Incident prostate cancer AUROC: 0.662 [0.655, 0.67] Genotyping array
PPM001645 PGS000719
(PRS_Prostate)
PSS000860|
European Ancestry|
400,812 individuals
PGP000135 |
Jia G et al. JNCI Cancer Spectr (2020)
Reported Trait: Incident prostate cancer AUROC: 0.669 [0.661, 0.676] family history of cancer (in first-degree relatives), genotyping array
PPM001674 PGS000733
(PHS46+African)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR top 20% vs. bottom 20%): 4.42 [4.16, 4.67] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001676 PGS000733
(PHS46+African)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR top 2% vs. middle 40%): 3.67 [3.48, 3.87] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001678 PGS000733
(PHS46+African)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR bottom 20% vs. middle 40%): 0.51 [0.49, 0.52] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001680 PGS000733
(PHS46+African)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (top 20% vs. bottom 20%): 4.71 [4.38, 5.05] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001682 PGS000733
(PHS46+African)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (top 2% vs. middle 40%): 3.89 [3.64, 4.13] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001684 PGS000733
(PHS46+African)
PSS000874|
African Ancestry|
6,271 individuals
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (bottom 20% vs. middle 40%): 0.5 [0.48, 0.52] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001790 PGS000741
(PCa_PHS2)
PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer (age at diagnosis) Hazard ratio (HR, top 20% vs. bottom 20%): 5.32 [4.99, 5.7]
PPM001791 PGS000741
(PCa_PHS2)
PSS000924|
Multi-ancestry (including European)|
71,856 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer (age at diagnosis) Hazard ratio (HR, top 20% vs. bottom 20%): 5.54 [5.18, 5.93]
PPM001792 PGS000741
(PCa_PHS2)
PSS000923|
Multi-ancestry (excluding European)|
2,382 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer (age at diagnosis) Hazard ratio (HR, top 20% vs. bottom 20%): 4.49 [3.23, 6.33]
PPM001793 PGS000741
(PCa_PHS2)
PSS000922|
Multi-ancestry (excluding European)|
6,253 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer (age at diagnosis) Hazard ratio (HR, top 20% vs. bottom 20%): 2.54 [2.08, 3.1]
PPM001797 PGS000741
(PCa_PHS2)
PSS000922|
Multi-ancestry (excluding European)|
6,253 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Aggressive prostate cancer (age at diagnosis) Hazard ratio (HR, top 20% vs. bottom 20%): 2.43 [1.51, 4.05]
PPM001798 PGS000741
(PCa_PHS2)
PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer mortality (age at death) Hazard ratio (HR, top 20% vs. bottom 20%): 5.68 [5.07, 6.46]
PPM001800 PGS000741
(PCa_PHS2)
PSS000924|
Multi-ancestry (including European)|
71,856 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer in men with a family history of prostate cancer β: 2.06 Hazard ratio (HR, top 20% vs. bottom 20%): 4.8
PPM001795 PGS000741
(PCa_PHS2)
PSS000924|
Multi-ancestry (including European)|
71,856 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Aggressive prostate cancer (age at diagnosis) Hazard ratio (HR, top 20% vs. bottom 20%): 5.62 [5.25, 6.05]
PPM001803 PGS000741
(PCa_PHS2)
PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer β: 2.16 Hazard ratio (HR, top 20% vs. bottom 20%): 5.12
PPM001804 PGS000741
(PCa_PHS2)
PSS000924|
Multi-ancestry (including European)|
71,856 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer β: 2.1 Hazard ratio (HR, top 20% vs. bottom 20%): 4.93
PPM001805 PGS000741
(PCa_PHS2)
PSS000923|
Multi-ancestry (excluding European)|
2,382 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer β: 1.73 Hazard ratio (HR, top 20% vs. bottom 20%): 3.6
PPM001806 PGS000741
(PCa_PHS2)
PSS000922|
Multi-ancestry (excluding European)|
6,253 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer β: 1.1 Hazard ratio (HR, top 20% vs. bottom 20%): 2.16
PPM001807 PGS000741
(PCa_PHS2)
PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer mortality in men with a family history of prostate cancer β: 2.2 Hazard ratio (HR, top 20% vs. bottom 20%): 5.29
PPM001794 PGS000741
(PCa_PHS2)
PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Aggressive prostate cancer (age at diagnosis) Hazard ratio (HR, top 20% vs. bottom 20%): 5.88 [5.48, 6.34]
PPM001796 PGS000741
(PCa_PHS2)
PSS000923|
Multi-ancestry (excluding European)|
2,382 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Aggressive prostate cancer (age at diagnosis) Hazard ratio (HR, top 20% vs. bottom 20%): 5.16 [3.45, 7.78]
PPM001799 PGS000741
(PCa_PHS2)
PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer in men with a family history of prostate cancer β: 1.98 Hazard ratio (HR, top 20% vs. bottom 20%): 4.48
PPM001801 PGS000741
(PCa_PHS2)
PSS000923|
Multi-ancestry (excluding European)|
2,382 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer in men with a family history of prostate cancer β: 1.89 Hazard ratio (HR, top 20% vs. bottom 20%): 4.17
PPM001802 PGS000741
(PCa_PHS2)
PSS000922|
Multi-ancestry (excluding European)|
6,253 individuals
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Reported Trait: Prostate cancer in men with a family history of prostate cancer β: 1.11 Hazard ratio (HR, top 20% vs. bottom 20%): 2.22
PPM002489 PGS000741
(PCa_PHS2)
PSS001118|
Ancestry Not Reported|
3,279 individuals
PGP000219 |
Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Prostate cancer mortality (age at death) HR: 3.41 [2.78, 4.17]
PPM002490 PGS000741
(PCa_PHS2)
PSS001118|
Ancestry Not Reported|
3,279 individuals
PGP000219 |
Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Prostate cancer (age at diagnosis) HR: 5.35 [4.97, 5.76]
PPM002491 PGS000741
(PCa_PHS2)
PSS001118|
Ancestry Not Reported|
3,279 individuals
PGP000219 |
Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Aggressive prostate cancer (age at diagnosis) HR: 3.78 [3.45, 4.13]
PPM002492 PGS000741
(PCa_PHS2)
PSS001118|
Ancestry Not Reported|
3,279 individuals
PGP000219 |
Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021)
|Ext.
Reported Trait: Prostate cancer mortality (age at death) HR: 2.45 [1.99, 2.97]
β: 0.9
Family history of prostate cancer, alcohol intake, diabetes history
PPM001808 PGS000742
(PHS166)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Reported Trait: Prostate cancer (age of onset) Hazard Ratio (HR, top 5% vs. middle 40%): 4.45 [3.68, 5.06]
PPM001809 PGS000742
(PHS166)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Reported Trait: Prostate cancer (age of onset) Hazard Ratio (HR, top 20% vs. bottom 20%): 7.85 [6.04, 9.33]
PPM001810 PGS000742
(PHS166)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Reported Trait: Prostate cancer (age of onset) Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.37 [0.33, 0.4]
PPM001814 PGS000742
(PHS166)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Reported Trait: Clinically significant prostate cancer (age at onset) Hazard Ratio (HR, top 5% vs. middle 40%): 5.09 [3.84, 6.05]
PPM001815 PGS000742
(PHS166)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Reported Trait: Clinically significant prostate cancer (age at onset) Hazard Ratio (HR, top 20% vs. bottom 20%): 9.45 [6.17, 11.79]
PPM001816 PGS000742
(PHS166)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Reported Trait: Clinically significant prostate cancer (age at onset) Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.34 [0.29, 0.39]
PPM001820 PGS000742
(PHS166)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Reported Trait: Non-clinically significant prostate cancer (age at onset) Hazard Ratio (HR, top 5% vs. middle 40%): 4.28 [3.49, 4.96]
PPM001821 PGS000742
(PHS166)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Reported Trait: Non-clinically significant prostate cancer (age at onset) Hazard Ratio (HR, top 20% vs. bottom 20%): 7.47 [5.49, 9.07]
PPM001822 PGS000742
(PHS166)
PSS000926|
European Ancestry|
6,411 individuals
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Reported Trait: Non-clinically significant prostate cancer (age at onset) Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.37 [0.33, 0.42]
PPM001907 PGS000751
(PRS_PrCa_EuropeanWeighted)
PSS000953|
Hispanic or Latin American Ancestry|
4,324 individuals
PGP000156 |
Du Z et al. Int J Cancer (2019)
Reported Trait: Prostate cancer Odds ratio (OR, top 10% vs. middle 50%): 3.1 [2.55, 3.76] Age, study, PCs(1-10) Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF  ≥  0.001 and imputation r^2  ≥ 0.3 in Latino men.
PPM001908 PGS000751
(PRS_PrCa_EuropeanWeighted)
PSS000953|
Hispanic or Latin American Ancestry|
4,324 individuals
PGP000156 |
Du Z et al. Int J Cancer (2019)
Reported Trait: Prostate cancer Odds ratio (OR, top 1% vs. middle 50%): 4.02 [2.46, 6.55] Age, study, PCs(1-10) Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF  ≥  0.001 and imputation r^2  ≥ 0.3 in Latino men.
PPM001909 PGS000751
(PRS_PrCa_EuropeanWeighted)
PSS000953|
Hispanic or Latin American Ancestry|
4,324 individuals
PGP000156 |
Du Z et al. Int J Cancer (2019)
Reported Trait: Prostate cancer Odds ratio (OR, bottom 10% vs. middle 50%): 0.38 [0.28, 0.51] Age, study, PCs(1-10) Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF  ≥  0.001 and imputation r^2  ≥ 0.3 in Latino men.
PPM001910 PGS000751
(PRS_PrCa_EuropeanWeighted)
PSS000953|
Hispanic or Latin American Ancestry|
4,324 individuals
PGP000156 |
Du Z et al. Int J Cancer (2019)
Reported Trait: Prostate cancer Odds ratio (OR, bottom 1% vs. middle 50%): 0.25 [0.09, 0.67] Age, study, PCs(1-10) Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF  ≥  0.001 and imputation r^2  ≥ 0.3 in Latino men.
PPM002066 PGS000795
(CC_Prostate_IV)
PSS001023|
European Ancestry|
184,225 individuals
PGP000186 |
Kachuri L et al. Nat Commun (2020)
Reported Trait: Incident prostate cancer HR: 1.77 [1.72, 1.82] AUROC: 0.769
C-index: 0.768 (0.004)
: 0.51 Age at assessment, family history of prostate cancer, genotyping array, PCs(1-15), family history of prostate cancer C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years.
PPM002069 PGS000795
(CC_Prostate_IV)
PSS001023|
European Ancestry|
184,225 individuals
PGP000186 |
Kachuri L et al. Nat Commun (2020)
Reported Trait: Incident prostate cancer AUROC: 0.766
C-index: 0.763 (0.004)
: 0.496 Age, genotyping array, PCs(1-15) C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years.
PPM002516 PGS000878
(PRS4_PC)
PSS001135|
East Asian Ancestry|
638 individuals
PGP000224 |
Oh JJ et al. Front Oncol (2020)
Reported Trait: Prostate cancer AUROC: 0.637 Odds Ratio (OR, top 25% vs bottom 25%): 4.2 [2.32, 7.98] Age
PPM002522 PGS000881
(GRS72_PCa)
PSS001140|
European Ancestry|
1,237 individuals
PGP000227 |
Xu J et al. Prostate (2021)
Reported Trait: Number of positive prostate cancer tumour cores at diagnostic biposy OR: 1.23 [1.06, 1.41] Age at diagnosis, study site
PPM002523 PGS000881
(GRS72_PCa)
PSS001140|
European Ancestry|
1,237 individuals
PGP000227 |
Xu J et al. Prostate (2021)
Reported Trait: Number of positive prostate cancer tumour cores at surveillance biposy OR: 1.26 [1.11, 1.44] Age at diagnosis, study site
PPM002524 PGS000881
(GRS72_PCa)
PSS001140|
European Ancestry|
1,237 individuals
PGP000227 |
Xu J et al. Prostate (2021)
Reported Trait: Bilateral positive prostate cancer tumor cores at diagnostic biopsy OR: 1.27 [1.01, 1.61] Age at diagnosis, study site
PPM002525 PGS000881
(GRS72_PCa)
PSS001140|
European Ancestry|
1,237 individuals
PGP000227 |
Xu J et al. Prostate (2021)
Reported Trait: Bilateral positive prostate cancer tumor cores at surveillance biopsy OR: 1.19 [1.04, 1.36] Age at diagnosis, study site
PPM008953 PGS001291
(GBE_cancer1044)
PSS007636|
African Ancestry|
6,497 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Prostate cancer AUROC: 0.92615 [0.91516, 0.93714] : 0.36445
Incremental AUROC (full-covars): 0.0009
PGS R2 (no covariates): 0.00433
PGS AUROC (no covariates): 0.55467 [0.51548, 0.59387]
age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008954 PGS001291
(GBE_cancer1044)
PSS007637|
East Asian Ancestry|
1,704 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Prostate cancer AUROC: 0.97011 [0.94971, 0.99051] : 0.40156
Incremental AUROC (full-covars): 0.00138
PGS R2 (no covariates): 0.01286
PGS AUROC (no covariates): 0.63402 [0.52345, 0.74459]
age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008955 PGS001291
(GBE_cancer1044)
PSS007638|
European Ancestry|
24,905 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Prostate cancer AUROC: 0.91101 [0.90322, 0.91879] : 0.29589
Incremental AUROC (full-covars): 0.01454
PGS R2 (no covariates): 0.03164
PGS AUROC (no covariates): 0.65437 [0.62906, 0.67968]
age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008956 PGS001291
(GBE_cancer1044)
PSS007639|
South Asian Ancestry|
7,831 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Prostate cancer AUROC: 0.9026 [0.88127, 0.92393] : 0.25031
Incremental AUROC (full-covars): 0.01068
PGS R2 (no covariates): 0.02013
PGS AUROC (no covariates): 0.62511 [0.56383, 0.6864]
age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008957 PGS001291
(GBE_cancer1044)
PSS007640|
European Ancestry|
67,425 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Prostate cancer AUROC: 0.8892 [0.88431, 0.89409] : 0.27234
Incremental AUROC (full-covars): 0.01941
PGS R2 (no covariates): 0.02942
PGS AUROC (no covariates): 0.63978 [0.62584, 0.65373]
age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM009346 PGS001805
(portability-PLR_185)
PSS009275|
European Ancestry|
8,501 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.1532 [0.1323, 0.1739] sex, age, birth date, deprivation index, 16 PCs
PPM009347 PGS001805
(portability-PLR_185)
PSS009049|
European Ancestry|
1,468 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.168 [0.1175, 0.2176] sex, age, birth date, deprivation index, 16 PCs
PPM009348 PGS001805
(portability-PLR_185)
PSS008603|
European Ancestry|
2,749 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0919 [0.0546, 0.129] sex, age, birth date, deprivation index, 16 PCs
PPM009349 PGS001805
(portability-PLR_185)
PSS008381|
Greater Middle Eastern Ancestry|
664 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.1243 [0.0476, 0.1996] sex, age, birth date, deprivation index, 16 PCs
PPM009350 PGS001805
(portability-PLR_185)
PSS008157|
South Asian Ancestry|
3,182 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0832 [0.0484, 0.1177] sex, age, birth date, deprivation index, 16 PCs
PPM009351 PGS001805
(portability-PLR_185)
PSS007945|
East Asian Ancestry|
575 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0843 [0.0011, 0.1663] sex, age, birth date, deprivation index, 16 PCs
PPM009353 PGS001805
(portability-PLR_185)
PSS008829|
African Ancestry|
1,711 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0537 [0.006, 0.1011] sex, age, birth date, deprivation index, 16 PCs
PPM009352 PGS001805
(portability-PLR_185)
PSS007727|
African Ancestry|
844 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0638 [-0.0044, 0.1315] sex, age, birth date, deprivation index, 16 PCs
PPM011002 PGS002016
(portability-ldpred2_185)
PSS009275|
European Ancestry|
8,501 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.1489 [0.128, 0.1696] sex, age, birth date, deprivation index, 16 PCs
PPM011003 PGS002016
(portability-ldpred2_185)
PSS009049|
European Ancestry|
1,468 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.1605 [0.1099, 0.2103] sex, age, birth date, deprivation index, 16 PCs
PPM011004 PGS002016
(portability-ldpred2_185)
PSS008603|
European Ancestry|
2,749 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0944 [0.057, 0.1314] sex, age, birth date, deprivation index, 16 PCs
PPM011006 PGS002016
(portability-ldpred2_185)
PSS008157|
South Asian Ancestry|
3,182 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0875 [0.0528, 0.1219] sex, age, birth date, deprivation index, 16 PCs
PPM011007 PGS002016
(portability-ldpred2_185)
PSS007945|
East Asian Ancestry|
575 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0813 [-0.0018, 0.1634] sex, age, birth date, deprivation index, 16 PCs
PPM011008 PGS002016
(portability-ldpred2_185)
PSS007727|
African Ancestry|
844 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0792 [0.011, 0.1466] sex, age, birth date, deprivation index, 16 PCs
PPM011009 PGS002016
(portability-ldpred2_185)
PSS008829|
African Ancestry|
1,711 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.0467 sex, age, birth date, deprivation index, 16 PCs
PPM011005 PGS002016
(portability-ldpred2_185)
PSS008381|
Greater Middle Eastern Ancestry|
664 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Cancer of prostate Partial Correlation (partial-r): 0.1504 [0.0741, 0.225] sex, age, birth date, deprivation index, 16 PCs
PPM012760 PGS002240
(prscs_prostatecancer)
PSS009544|
European Ancestry|
687,352 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 2.14 [2.09, 2.19] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012770 PGS002240
(prscs_prostatecancer)
PSS009548|
South Asian Ancestry|
15,256 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 2.54 [1.98, 3.26] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012765 PGS002240
(prscs_prostatecancer)
PSS009540|
African Ancestry|
15,236 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 1.43 [1.21, 1.69] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012739 PGS002241
(ldpred_prostatecancer)
PSS009520|
European Ancestry|
110,597 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 1.79 [1.68, 1.91] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012743 PGS002241
(ldpred_prostatecancer)
PSS009516|
East Asian Ancestry|
178,726 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 1.69 [1.64, 1.74] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012747 PGS002241
(ldpred_prostatecancer)
PSS009528|
European Ancestry|
69,422 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 1.8 [1.72, 1.88] birth year, 10 PCs (+/- dataset-specific technical covariates)
PPM012751 PGS002241
(ldpred_prostatecancer)
PSS009536|
European Ancestry|
25,696 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 1.66 [1.57, 1.76] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012755 PGS002241
(ldpred_prostatecancer)
PSS009532|
African Ancestry|
1,535 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 1.19 [0.91, 1.55] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012759 PGS002241
(ldpred_prostatecancer)
PSS009544|
European Ancestry|
687,352 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 1.91 [1.86, 1.96] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012764 PGS002241
(ldpred_prostatecancer)
PSS009540|
African Ancestry|
15,236 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 1.35 [1.14, 1.61] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012769 PGS002241
(ldpred_prostatecancer)
PSS009548|
South Asian Ancestry|
15,256 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 2.21 [1.73, 2.81] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012735 PGS002241
(ldpred_prostatecancer)
PSS009524|
European Ancestry|
258,402 individuals
PGP000271 |
Mars N et al. Cell Genom (2022)
Reported Trait: Prostate cancer OR: 1.96 [1.91, 2.01] age, 10 PCs (+/- dataset-specific technical covariates)
PPM012919 PGS002268
(PRS_csPCa)
PSS009617|
East Asian Ancestry|
1,133 individuals
PGP000298 |
Song SH et al. Investig Clin Urol (2022)
Reported Trait: Clinically significant prostate cancer AUROC: 0.7 [0.667, 0.734] OR (very high vs moderate group): 4.92

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000123 Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28010
[
  • 10,810 cases
  • , 190,706 controls
]
,
100.0 % Male samples
European GERA, UKB
PSS001135 Cases are individuals with prostate cancer. 80% of the cases are diagnosed with prostate cancer with a gleason score of ≥ 7.
[
  • 514 cases
  • , 124 controls
]
,
100.0 % Male samples
East Asian
(Korean)
NR
PSS001140 All individuals were prostate cancer cases undergoing active surveillance. Patients with favourable-risk prostate cancer and low-volume favourable intermediate-risk prostate cancer were enrolled. Favorable‐risk PCa was defined as Gleason grade group (GG) = 1 and prostate‐specific antigen (PSA) < 10 ng/ml. Low‐volume favorable intermediate‐risk in our study was defined as ≤2 positive cores, and only one of the following characteristics: GG ≤ 2 and/or PSA 10–20 ng/ml. At diagnostic biopsy 765 individuals had 1 tumour core, 272 had 2 tumour cores and 152 had ≥3 tumour cores. Of the individuals with 1, 2 or ≥3 positive cores at diagnostic biopsy, 1127 were unilateral and 95 were bilateral. At any surveillance biopsy 408 individuals had 1 tumour core, 297 had 2 tumour cores and 506 had ≥3 tumour cores. Of the individuals with 1, 2 or ≥3 positive cores at any surveillance biopsy, 635 were unilateral and 582 were bilateral. 1,237 individuals,
100.0 % Male samples
Mean = 65.16 years European JHH, NSUHS
PSS008157 3,182 individuals South Asian India (South Asia) UKB
PSS009594
[
  • 453 cases
  • , 4,127 controls
]
,
100.0 % Male samples
Not reported TCGA
PSS009617
[
  • 311 cases
  • , 822 controls
]
,
100.0 % Male samples
East Asian
(Korean)
NR
PSS007727 844 individuals African American or Afro-Caribbean Carribean UKB
PSS009275 8,501 individuals European UK (+ Ireland) UKB
PSS000446 National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9.
[
  • 3,617 cases
  • , 55,509 controls
]
,
100.0 % Male samples
European
(Finnish)
FinnGen
PSS000447 National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9.
[
  • 1,172 cases
  • , 47,679 controls
]
European
(Finnish)
FinnGen
PSS000041 For each cohort core data on disease status, age at diagnosis (age at observation or questionnaire for controls), family history of PrCa, and clinical factors for cases (for example, PSA at diagnosis and Gleason score) was extracted
[
  • 46,939 cases
  • , 27,910 controls
]
,
100.0 % Male samples
European 42 cohorts
  • APCB
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPS
  • ,EPIC
  • ,ERSPC
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,HZ
  • ,IMPACT
  • ,IPO-Porto
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT_PC
  • ,PCMUS
  • ,PCPT
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,Poland
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SAAR
  • ,SEARCH
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,SWOG-SELECT
  • ,TAMPERE
  • ,TOR
  • ,UKGPCS
These samples (OncoArray) were also used in the GWAS meta-analysis
PSS009632
[
  • 54,564 cases
  • , 37,059 controls
]
,
100.0 % Male samples
European BPC3, CGEMS, Ghana, PEGASUS GENEVA, ICPCG, ONCO
PSS009633
[
  • 5,505 cases
  • , 5,370 controls
]
,
100.0 % Male samples
African American or Afro-Caribbean BPC3, CGEMS, Ghana, PEGASUS GENEVA, ICPCG, ONCO
PSS009633
[
  • 1,574 cases
  • , 1,483 controls
]
,
100.0 % Male samples
Asian unspecified BPC3, CGEMS, Ghana, PEGASUS GENEVA, ICPCG, ONCO
PSS009633
[
  • 54,564 cases
  • , 37,059 controls
]
,
100.0 % Male samples
European BPC3, CGEMS, Ghana, PEGASUS GENEVA, ICPCG, ONCO
PSS009633
[
  • 461 cases
  • , 452 controls
]
,
100.0 % Male samples
Sub-Saharan African
(Ghanaian)
BPC3, CGEMS, Ghana, PEGASUS GENEVA, ICPCG, ONCO
PSS009633
[
  • 2,170 cases
  • , 2,068 controls
]
,
100.0 % Male samples
Hispanic or Latin American BPC3, CGEMS, Ghana, PEGASUS GENEVA, ICPCG, ONCO
PSS000840 Cases: clinically diagnosed or screen-detected prostate cancer. Controls: free of cancer
[
  • 2,738 cases
  • , 2,400 controls
]
,
100.0 % Male samples
European
(Finnish)
FinRSPC, PHD
PSS000841 Cases: clinically diagnosed with prostate cancer. Controls: free of cancer.
[
  • 2,283 cases
  • , 2,400 controls
]
,
100.0 % Male samples
European
(Finnish)
FinRSPC, PHD
PSS000843 Cases: screen-detected prostate cancer. Controls: free of cancer.
[
  • 455 cases
  • , 2,400 controls
]
,
100.0 % Male samples
European
(Finnish)
FinRSPC
PSS000842
[
  • 191 cases
  • , 2,400 controls
]
,
100.0 % Male samples
European
(Finnish)
FinRSPC, PHD
PSS000220 Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases
[
  • 26,419 cases
  • , 30,575 controls
]
,
100.0 % Male samples
European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS000221 Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases
[
  • 1,424 cases
  • , 3,013 controls
]
,
100.0 % Male samples
African unspecified Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS000222 Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases
[
  • 716 cases
  • , 1,185 controls
]
,
100.0 % Male samples
Asian unspecified Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS000223 Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases
[
  • 24,279 cases
  • , 26,377 controls
]
,
100.0 % Male samples
European Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS000224 Age at death due to prostate cancer.
[
  • 3,983 cases
  • , 30,575 controls
]
,
100.0 % Male samples
Mean = 70.0 years
IQR = [63.0, 76.0] years
European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS008829 1,711 individuals African unspecified Nigeria (West Africa) UKB
PSS009648
[
  • 240 cases
  • , 751 controls
]
,
100.0 % Male samples
European MDC
PSS009649
[
  • 235 cases
  • , 765 controls
]
,
100.0 % Male samples
European VIP
PSS009650
[
  • 475 cases
  • , 1,516 controls
]
,
100.0 % Male samples
European NR
PSS000860 Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Prostate=(ICD-9 = 185 or ICD-10 = C61) Median = 5.8 years
[
  • 4,430 cases
  • , 396,382 controls
]
,
46.5 % Male samples
European UKB
PSS000068 Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.
[
  • 2,148 cases
  • , 6,648 controls
]
,
100.0 % Male samples
Range = [50.0, 69.0] years European ProtecT
PSS000068 Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.
[
  • 4,099 cases
  • , 960 controls
]
,
100.0 % Male samples
Range = [50.0, 69.0] years European SEARCH
PSS000068 Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.
[
  • 3,157 cases
  • , 0 controls
]
,
100.0 % Male samples
Range = [50.0, 60.0] years European UKGPCS
PSS000069 Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7. Median = 13.0 years
[
  • 1,089 cases
  • , 3,878 controls
]
,
100.0 % Male samples
Range = [55.0, 71.0] years European
(Finnish)
ERSPC
PSS000874 Clinically significant cancer were any of: Gleason score ≥ 7, stage T3-T4, PSA concentration ≥ 10 ng/mL, pelvic lymph nodal metastasis or distant metastasis.
[
  • 3,031 cases
  • , 3,240 controls
]
,
100.0 % Male samples
African unspecified 18 cohorts
  • BioVU
  • ,CPDR
  • ,CeRePP
  • ,EPICAP
  • ,KARUPROSTATE
  • ,MIAMI-WFPCS
  • ,MOFFITT
  • ,NMHS
  • ,PCPT
  • ,PCaP
  • ,PROtEuS
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SELECT
  • ,SFPCS
  • ,UKGPCS
  • ,WUGS
PRACTICAL consortium
PSS008381 664 individuals Greater Middle Eastern (Middle Eastern, North African or Persian) Iran (Middle East) UKB
PSS001023 Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases.
[
  • 4,740 cases
  • , 179,485 controls
]
,
100.0 % Male samples
European UKB
PSS000552 PheCode:185; ICD9CM:185, 233.4, V10.46; ICD10CM:C61, D07.5
[
  • 1,190 cases
  • , 4,417 controls
]
European MGI
PSS000075 Breast and prostate cancer cases were defined on the basis of age at diagnosis, whichever occurred first. If breast and prostate cancer occurred at the same time, individuals were treated as patients with breast cancer.
[
  • 212 cases
  • , 1,313 controls
]
,
100.0 % Male samples
European Self-reported European ancestry 37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
PSS000076
[
  • 2,012 cases
  • , 1,313 controls
]
,
100.0 % Male samples
European Self-reported European ancestry 37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
PSS000077
[
  • 53 cases
  • , 1,313 controls
]
,
100.0 % Male samples
European Self-reported European ancestry 37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
PSS000501 Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. NSGI controls had a minimum of 1 year clincal history available in the EHR and were exlucded if any ICD9/10 diagnosis of cancer was present at any time in the EHR. Men who tested positive for RPVs in any prostate cancer susceptibility gene were exlcuded from further analysis.
[
  • 1,972 cases
  • , 1,919 controls
]
,
100.0 % Male samples
European AG, JHH, NSGHI
PSS000502 Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing.
[
  • 744 cases
  • , 295 controls
]
,
100.0 % Male samples
European AG, JHH
PSS000503 Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing.
[
  • 1,133 cases
  • , 1,172 controls
]
,
100.0 % Male samples
European AG, JHH
PSS000573 PheCode:185; ICD9:185, 233.4; ICD10:C61, D07.5
[
  • 3,012 cases
  • , 29,652 controls
]
European UKB
PSS007945 575 individuals East Asian China (East Asia) UKB
PSS000595
[
  • 1,586 cases
  • , 1,047 controls
]
,
100.0 % Male samples
African unspecified CAUG
PSS000596
[
  • 6,852 cases
  • , 193,117 controls
]
,
100.0 % Male samples
European UKB
PSS000924 Cases numbers refer to 'any prostate cancer'. Of those, 24279 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 3908 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 39,445 individuals had a family history of prostate cancer (≥1 first degree relative affected).
[
  • 45,479 cases
  • , 26,377 controls
]
,
100.0 % Male samples
Mean = 66.0 years
IQR = [60.0, 71.0] years
European, NR 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
PSS000925 Cases numbers refer to 'any prostate cancer'. Of those, 24279 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 3908 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis.
[
  • 45,479 cases
  • , 26,377 controls
]
,
100.0 % Male samples
Mean = 66.0 years
IQR = [60.0, 71.0] years
European, NR 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
PSS000925 Cases numbers refer to 'any prostate cancer'. Of those, 716 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 57 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis.
[
  • 1,197 cases
  • , 1,185 controls
]
,
100.0 % Male samples
Mean = 68.0 years
IQR = [62.0, 74.0] years
Asian unspecified, NR 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
PSS000925 Cases numbers refer to 'any prostate cancer'. Of those, 1424 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 18 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis.
[
  • 3,240 cases
  • , 3,013 controls
]
,
100.0 % Male samples
Mean = 62.0 years
IQR = [56.0, 68.0] years
African unspecified, NR 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
PSS000922 Cases numbers refer to 'any prostate cancer'. Of those, 1424 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 18 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 5557 individuals had a family history of prostate cancer (≥1 first degree relative affected).
[
  • 3,240 cases
  • , 3,013 controls
]
,
100.0 % Male samples
Mean = 62.0 years
IQR = [56.0, 68.0] years
African unspecified, NR 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
PSS000923 Cases numbers refer to 'any prostate cancer'. Of those, 716 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 57 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 1028 individuals had a family history of prostate cancer (≥1 first degree relative affected).
[
  • 1,197 cases
  • , 1,185 controls
]
,
100.0 % Male samples
Mean = 68.0 years
IQR = [62.0, 74.0] years
Asian unspecified, NR 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
PSS000926 Cases included individuals with any type of prostate cancer (PCa). For any clinically significant PCa, cases were defined as individuals with any of the following: Gleason score ≥ 7, stage T3-T4, PSA concentration ≥ 10 ng/mL, pelvic lymph nodal metastasis, or distant metastasis.
[
  • 1,583 cases
  • , 4,828 controls
]
,
100.0 % Male samples
European ProtecT, UKGPCS
PSS000105 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
IQR = [55.0, 63.0] years
European ProtecT
PSS000105 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of aggressive prostate cancer (defined as any of Gleason score ≥7, stage T3-T4, PSA concentration ≥10 ng/mL, nodal metastasis, or distant metastasis)
[
  • 628 cases
]
,
100.0 % Male samples
Mean = 64.3 years
IQR = [60.2, 67.5] years
European ProtecT
PSS000106 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
IQR = [55.0, 63.0] years
European ProtecT
PSS000106 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of prostate cancer.
[
  • 1,583 cases
]
,
100.0 % Male samples
Mean = 63.4 years
IQR = [59.0, 67.5] years
European ProtecT
PSS000107 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
IQR = [55.0, 63.0] years
European ProtecT
PSS000107 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of very aggressive prostate cancer (defined as any of Gleason score ≥8, stage T3-4, positive nodes, or distant metastases)
[
  • 220 cases
]
,
100.0 % Male samples
European ProtecT
PSS003583 All individuals were BRCA1 carriers. BRCA1 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with prostate cancer.
[
  • 70 cases
  • , 380 controls
]
,
100.0 % Male samples
European 31 cohorts
  • BCFR
  • ,BCFR-CA
  • ,BCFR-UT
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CNIO
  • ,CONSIT_TEAM
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,GC-HBOC
  • ,GEMO
  • ,HEBCS
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,IOVHBOCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSUCCG
  • ,OUH
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
Additional cases and controls were obtained from UCHICAGO
PSS003584 All individuals were BRCA2 carriers. BRCA2 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with prostate cancer.
[
  • 141 cases
  • , 933 controls
]
,
100.0 % Male samples
European 36 cohorts
  • BCFR
  • ,BCFR-AU
  • ,BCFR-CA
  • ,BCFR-UT
  • ,BRICOH
  • ,CBCS
  • ,CNIO
  • ,CONSIT_TEAM
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSUCCG
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
Additional cases and controls were obtained from UCHICAGO
PSS009516
[
  • 5,192 cases
  • , 173,534 controls
]
,
100.0 % Male samples
East Asian
(Japanese)
BBJ
PSS009520
[
  • 1,202 cases
  • , 109,395 controls
]
,
100.0 % Male samples
European
(Estonian)
EB
PSS000953 In set 1 (1034 cases), prostate cancer cases were identified by linking with the cancer registries in Hawaii and California. In set 2 (1192 cases) cases were indiviuals with prostate cancer determined by cancer diagnosis, enrollment in prostate cancer studies at University of Texas M.D. Ancerson Cancer Centre or by biposy confirmation.
[
  • 2,226 cases
  • , 2,098 controls
]
,
100.0 % Male samples
Hispanic or Latin American LAAPC, MDA, MEC, SABOR
PSS009049 1,468 individuals European Poland (NE Europe) UKB
PSS009524
[
  • 8,709 cases
  • , 249,693 controls
]
,
100.0 % Male samples
European
(Finnish)
FinnGen
PSS007636
[
  • 199 cases
  • , 6,298 controls
]
African unspecified UKB
PSS007637
[
  • 9 cases
  • , 1,695 controls
]
East Asian UKB
PSS007638
[
  • 441 cases
  • , 24,464 controls
]
European non-white British ancestry UKB
PSS007639
[
  • 80 cases
  • , 7,751 controls
]
South Asian UKB
PSS007640
[
  • 1,563 cases
  • , 65,862 controls
]
European white British ancestry UKB Testing cohort (heldout set)
PSS009528
[
  • 2,224 cases
  • , 67,198 controls
]
,
100.0 % Male samples
European Norwegian HUNT
PSS009532
[
  • 80 cases
  • , 1,455 controls
]
,
100.0 % Male samples
African American or Afro-Caribbean MGBB
PSS009536
[
  • 1,593 cases
  • , 24,103 controls
]
,
100.0 % Male samples
European MGBB
PSS009540
[
  • 199 cases
  • , 7,419 controls
]
,
100.0 % Male samples
African unspecified UKB
PSS009540
[
  • 199 cases
  • , 7,419 controls
]
,
100.0 % Male samples
African unspecified UKB
PSS009544
[
  • 7,429 cases
  • , 336,247 controls
]
,
100.0 % Male samples
European British UKB
PSS009544
[
  • 7,429 cases
  • , 336,247 controls
]
,
100.0 % Male samples
European British UKB
PSS009548
[
  • 72 cases
  • , 7,556 controls
]
,
100.0 % Male samples
South Asian UKB
PSS009548
[
  • 72 cases
  • , 7,556 controls
]
,
100.0 % Male samples
South Asian UKB
PSS000975 Cases were defined as having a biopsy-confirmed prostate cancer documented by a pathology report or at least two prostate cancer-related billing codes any time before or within 6 months of the date of blood collection.
[
  • 67 cases
  • , 457 controls
]
,
100.0 % Male samples
African unspecified MGBB Formerly known as Partners healthcare Biobank (PHB)
PSS000976 Cases were defined as having a biopsy-confirmed prostate cancer documented by a pathology report or at least two prostate cancer-related billing codes any time before or within 6 months of the date of blood collection.
[
  • 1,554 cases
  • , 10,918 controls
]
,
100.0 % Male samples
European MGBB Formerly known as Partners healthcare Biobank (PHB)
PSS008603 2,749 individuals European Italy (South Europe) UKB
PSS000280 Primary tumor samples from TCGA
[
  • 421 cases
  • , 0 controls
]
,
100.0 % Male samples
Mean = 62.0 years
Sd = 7.0 years
European TCGA
PSS000280
[
  • 0 cases
  • , 6,407 controls
]
,
100.0 % Male samples
European eMERGE
PSS000983 Cases were individuals with malignant prostate cancer. All individuals (cases and controls) were carriers of rare pathogenic, likely pathogenic and/or deleterious germline variants in ATM, BRCA2, CHEK2, and HOXB13 genes.
[
  • 3,568 cases
  • , 77,526 controls
]
,
100.0 % Male samples
European UKB
PSS001118 Cases are individuals with prostate cancer. Of the 2163 cases, 1403 are aggressive prostate cancer cases defined as disease typically requiring treatment: Gleason score ≥7, clinical stage T3-T4, PSA concentration ≥10 ng/mL, or nodal/distant metastasis. 278 prostate cancer cases were fatal.
[
  • 2,163 cases
  • , 1,116 controls
]
,
100.0 % Male samples
Median = 78.0 years
IQR = [72.3, 84.1] years
Not reported COSM Sample overlap exists between this dataset and the dataset used to develop/train Karunamuni et al's PGS (PGS000741)